Skip to main content

Maze Therapeutics, Inc Investor Event Transcript, Nov 10, 2026

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics said its renal study enrolled over 50 patients, exceeding the prior target of 30 to 45. MZE782 began on schedule, with PKU data expected in 27, while a chronic kidney disease study is planned to start in 2027. AI summary

Investor Event Transcript 2026-11-10 For: 2026-12-31
Added on November 15, 2026

Conference Transcript - MAZE 2026-11-10

Speaker 1

Good afternoon, and thank you for joining Guggenheim's third annual Healthcare Innovations Conference. I'm Dev Chit, one of the therapeutic analysts at Guggenheim, and it's my pleasure to welcome Jason Coloma, the CEO of Maze Therapeutics, as our next presenting company. Thank you so much, Jason, for making time for us. Yeah, thanks for having us. Well, you just put up the quarterly update yesterday, and maybe we can pick it up from there because the study is fully enrolled and maybe over-enrolled. And from what we understand, you have a better handle of baselines right now versus last year. So, you know, maybe walk us through what kind of patients we'll get to see.

Jason Coloma, CEO

N27. Yeah, I think it's, you know, for people that are out there that are not familiar with us, you know, we use genetics as our handle to develop small molecule programs for programs like APL, one kidney disease, and for diseases like that. And we had our earnings announcement yesterday, and I think a really positive trend in what we saw in enrollment. We had talked about this, that there were a few factors that would be helpful in kind of thinking about enrollment from the administrative analysis that we had published earlier. One is, I think there's just more disease awareness from a lot of the efforts that are happening, not just from the companies that are sponsors in the trials, but also more importantly, the overall community, the nephrology community, the patient advocacy groups. So I think there's just a larger awareness around the disease and the importance of testing to at least know the information that might direct you right now, know approved therapies for 8-1-1 kidney disease, but at the same time, it might help them direct them to a study. And at least have clarity about why they might be suffering from the disease that they have. So I think that was incredibly helpful. I think the other thing is just in the sense of what we've been able to accomplish operationally, which was, you know, to be able to adjust. That's why we did some of the administrative analysis at that interim to really adjust what we were doing operationally, what sites were going to be the most productive, how do we engage better with the community. So some of the adjustments we've been doing there have obviously been helpful. And I think the third thing, which was incredibly helpful, is we had data. Part of the idea that we took the administrative analysis, it really does help engage the nephrologists as well as the patients on why they might want to consider participating in a study. And I think all three of those things really helped us in the sense of being able to think about enrollment. We had talked about and guided previously that we would have, across three different cohorts, 10 to 15 patients. So that's 30 to 45. We've actually exceeded that, over 50 patients enrolled into the study. And I think that just speaks to a lot of the hard work that our team was able to do over the last few months. And I think when you think about that, Debjit, in the sense of what that means, in terms of the context, you know, other sponsor studies that were also in phase two had around 50 patients. So I think it was important to have a size of a study that was comparable to those in front of us or aside us in terms of 8-1-1 kidney disease. And I think for our team, it also gives us the confidence that we can enroll this study, the next study, right, in terms of the pivotal because of some of the things that we can carry forward in terms of tactics and strategies about how to enroll the study. I think that was a question mark for many investors, and I think we were able to make these adjustments. I think the other thing that we had talked about is we have a second program, SOC6A19 inhibitor, called MZE782. Earlier in the year, we had guided that we would be able to start that study by the middle of the year. We did that on time, as we had promised our investors. That's going very well as we've gotten that study launched. It could be best in class in PKU, which is, you know, we're seeing a lot of resurgence of interest in PKU as a disease, in particular other launches that have been very successful in the market, have really painted a picture of really sort of the unmet need that patients have. We're excited about being able to enroll that study and being able to have that data in 27. And the last thing is we're also using SOC inhibition in the context of chronic kidney disease, and what we described in our earnings was the ability to start that study in 2027. So a lot of things going great for the company in the sense of those studies. I think we also highlighted a few things that we've been able to do operationally, and then our balance sheet Strong that gets us through all of the different data catalysts that we will be upcoming, including April 1, SLC, PKU, NSLC, CKD. So a lot of good things going on at the company.

Speaker 1

Well, a lot to unpack there. So let's start with 829. Just refresh us on the differentiated mechanism of action for 829 versus an axiplin.

Jason Coloma, CEO

Yeah. So I think for those that are not as familiar with APR1 inhibitors, the concept is that under certain conditions, patients have this This overexpression of APR1s that really embed themselves in kidney cells or podocytes, causing eventually this nephrotoxicity. So at minimum, what you want to be able to do, because they become these ungated pores, if you will, in the kidney cells, is you want to block the pore from, you know, sort of allowing for certain things to coming into the cell. The other thing that you may want to do is not only just block the pores, but also disrupt the assembly of those pores from ever happening. So, you know, what was interesting as we started to generate our molecule, which was informed by not just genetics, but other things that we were able to do preclinically, we knew that we were binding to the poor, which was at a different location than compounds that have been described in the literature. They're both poor inhibitors, but they bind to a different site. We think that confers a different particular mechanism. The other thing that that, you know, what we saw is that we were incredibly more potent, at least in a preclinical model, looking at protein areas to read out. And to try to help understand that, we were trying to look at, you know, systematically what mechanism we might be able to do in terms of a pore inhibitor. So it turns out our compound, A29, not only blocks the pore, but it disrupts the assembly of the pore from ever forming, which is different than what's been described in the literature today of any other compound, which seemed to only be able to block the pore. Now, why is that important? It's because April 1 itself, it rapidly forms and reforms in the kidney. You know, there's some description in the literature that it reforms every, you know, 42 minutes or every hour. And so it doesn't really matter to us that you're blocking the pore. If they keep forming and keep embedding themselves in the podocyte, you know, you might still have the cell damage ultimately causing the issue. So the fact that we have this differentiated mechanism gives us at least a reason to believe we could have some improved efficacy. And we saw that at least in the preclinical data and hints of that in our early administrative analysis.

Speaker 1

Yes, so let's talk about the data from earlier this year. If you were just to focus on the FSGS patients, the differentiated mechanism did come about with a deeper protein urinary reduction. And if you take that forward, now that... The street seems to believe that the mechanism is going to be broadly applicable to AMKD patients. How should we think about the data that's going to get presented in March?

Jason Coloma, CEO

Yeah. Sorry, next year. Yeah, I think there were two important things that have kind of happened for 8-Ball-1 programs in the past month. One was I think people had this perception that only a small number of patients would benefit from an 8-Ball-1 inhibitor, you know, a very subset of what's called FSGS patients. And what we've seen, you know, starting with our data and reinforced with some recent data, is that this can work in a broader set of patients, both with or without diabetes. So I think in terms of the addressable patient population, this isn't a, you know, ultra-rare disease. This becomes an opportunity that could be, you know, hundreds of thousands of patients that can benefit from an APL1 inhibitor. So I think that's important, that the addressable patient population starts to be larger than what people thought. I think the other thing that was sort of a commentary from, you know, sort of investors was the fact that what's the regulatory framework to really kind of think about, you know, accelerated pathways to approval with 8.1 inhibitors? That's not well-established like it is in other kidney disease like IGAN or FSGS, and the good thing is there has been some additional analyses. There's an academic working group, Debjit, called Parasol that's been working with the FDA and the sponsors of all these different studies, and what they showed, and importantly, is that there could be a pathway to accelerated approval that is a biomarker, in this case, proteinuria or protein reduction, And I think that's really important because at least it sets the framework of what might be possible, that accelerated approval, and I think it starts to, you know, for investors, clarify that there can be a regulatory pathway for AMKD or 8-1-1 kidney disease. And so for us, if you go back to what we're doing, right, so if you think about FSGS, I think most investors would say clearly that it has effect. Clearly, this is a drug for those particular patients, albeit small, but at least in those particular patients, we can start to look for differentiation with our molecule versus what's been described, right? And I think a couple ways to kind of think about that. That one is... And from an efficacy standpoint, are we reducing proteinuria better than what's been described? I think we have. I think we have previously showed we don't, when we have an effect, you don't see patients with UACRs going up. They all tend to go down, which is good. And we're doing that on top of standard of care, including things like SGLT2, which wasn't really previously described. So I think if we're able to maintain, think about going forward, if we're able to maintain that type of competitive profile while still showing you have a very safe and tolerable compound, which we've been able to demonstrate to date, I think that itself lends itself to kind of be able to have further evidence and reinforces that we might have a best-in-class profile.

Speaker 1

So, the recent data that, or the data cut that was presented at ASN, it appeared like the US ER reductions were more of a function of exposure as opposed to baselines. The thought process is, are you comfortable with a dose that's going forward, or maybe are you leaving a little bit of efficacy on the table here?

Jason Coloma, CEO

Yeah, so I think, so we showed two pieces of new data at ASN, which is just additional detail of the patients that we had described at the administrative. One was, you know, exposure, and the other was UACR reduction over time. So let me just address the second one first, and I'll answer your question. And so what we noted, and I said this verbally when we had the data, but we didn't show it to ASN, was over a 12 to 13-week study, what you'd want to see is, you know, reduction over time. But more importantly, at that 12 to 13-week period, that you don't have this leveling off of the effect, but you actually see a deepening response, or at least a slope still going down. Because that gives you a reason to believe that with longer duration of treatment, you might even see better protein or reduction. And we've seen that before. Wherever you've seen that before, like IGAN, if you look at the old phase 2 data of the, you know, sort of the earlier IGAN programs, you know, they were in sort of the 20s, mid-20s in terms of UACR reduction over 12 to 13 weeks. But as you got to 48 weeks or longer, you see even deeper responses, right, 40, 50% reduction in UACR. So when you show a nephrologist 12- to 13-week data and you see that slope going down, that's really encouraging based off what they've seen before. The other piece of data that we showed was UACR exposure, which you kind of pointed out in thinking about what's the right dose. So one thing that we did talk about in our phase one is that we did have a positive food effect, which increases exposure with food. So one thing that we did for that first administrative cut is have patients that were fasting because we wanted to just kind of see what that would do to tolerability. And when we saw that administrative cut, it was one of the reasons we looked at it, was to say, oh, we can actually give it with food. Right? So one of the things that we did in our protocol amendment that you saw that we had talked about previously is that, you know, we can actually give it with or without food. That actually increases exposure. So we'll take a totality of the data when we see it. But that alone should think about, you know, that was incredibly informative to kind of adjust what we wanted to do from a trial perspective. Got it.

Speaker 1

So let's unpack the upcoming data a little bit. You'll have three subsets of patients here, right? FSGS, primary APOA1, AMKD patients, and then the diabetic cohort. How would you sort of measure success across USDA reductions?

Jason Coloma, CEO

Yeah, so we have three cohorts. One is FSGS, one is non-diabetic, and then there's diabetes patients. Probably a couple, you know, we have pretty much equal distribution across those from an enrollment standpoint, which is good. Over the 50 patients, pretty evenly distributed. And I think for the entire study, we've always talked about at least a 30% reduction across all of those patients to really sort of define that we see this type of effect, especially on top of standard of care, including SGLT2 inhibitors. So I think that's how we kind of think about, you know, sort of the totality of it. And then, of course, people can look at subsets of the data, including FSGS. And I think if you go back to, okay, if we can maintain that competitive sort of profile where we see UACRs going down, hopefully we don't see any of them going up relative to what other sponsors have showed. And then have the safety tolerability profile that makes us competitive. I think that's what people should look for. I think the other thing for diabetes, which is interesting, because clearly there's a signal between the two sponsors that have published data, albeit more modest and a little bit more nuanced, I think the question will be, can you identify a subset of patients where the effect size might be bigger, right? And whether that be biomarker-driven or maybe something else, what we did notice in the Amplified data, for example, is that they had talked about these are mostly non-FSGS diabetes patients, which you would infer there were some patients that had FSGS in the diabetes cohort. So I think we've arbitrarily created these three cohorts, FSGS, diabetes, non-diabetic. There's clearly patients that have diabetes with an FSGS histology or a result, right? And so how do we sort of incorporate that into our analysis and thinking? Because there might be a subset of patients where you have a disproportionate, that might be disproportionately seeing efficacy. And could you incorporate that into further studies later down the road? Got it.

Speaker 1

So early next year, we should get... The Accelerated Approval Cohort from the other sponsor. If that hits on both the co-primary endpoints, does that become the standard for the, you know, projected registration study for Maze? Or on the other scenario, as it just hits on proteinuria, for GFR you have to wait for a couple of years or two years, you know, which part do you choose and where does parasol fit in there?

Jason Coloma, CEO

Yeah, I mean, obviously, as many people will be looking to see what, you know, sort of comes out of that particular data set and the results of that. I think going back to this academic working group analysis, which is Parasol, that had worked a bit with the FDA, I think, you know, there's clear data for non-diabetic patients that proteinuria maps very well to EGFR outcome, which is good and could be the basis for accelerated approval, or it could be EGFR slope, right? And this is just an observational study that could be useful for interaction with the agency. And then I think, obviously, based off of that data, other sponsors' data, plus our own data, we can engage the agency on what's the right endpoint for our pivotal. Is it EGFR slope? Is it, you know, proteinuria? Or is it a combination? And I think, obviously, more to come on that because we're obviously still working through that.

Speaker 1

So when the other sponsors started the Phase 3 study or the Phase 2, 3 study, the way it started off, it's taken them a while to enroll, but now you're saying with your expansion cohort, it started to enroll a lot faster. You think this can be carried on into a registration study, and that will define how long it's going to take to, you know, get eight to nine to the market?

Jason Coloma, CEO

Yeah, I think if you go back to, one, there's, you know, just because of the other sponsors, plus all the work that's being done by the community, there's more disease awareness, there's more testing, there's more testing infrastructure and availability. And then on top of that, I think having data to engage the overall community allows for people to say, hey, you should think about enrolling in a study, especially if you're not responding to standard of care. So I think that's all helpful. And I think this is one of those examples, you know, especially in you see this in some clinical trials where having someone in front of you actually is helpful for that in a sense of understanding how you might be able to drive enrollment. And then you can see it just in our own numbers, right? You know, where we were, you know, during the administrative analysis to where we are now, you know, being able to enroll that many patients in a pretty short amount of time, enrolling about the order of magnitude that both other sponsors have done but in a shorter amount of time overall gives us the confidence to say if we implement some of these activities and probably maybe even expand on some of the things we've done operationally, you know, confidence that we can not only just enroll the study but do it in a shorter timeframe. And we've done that in the phase two. So I think that gives us at least a reason to believe why we might be able to be successful in shortening the timelines in our pivotal. Got it.

Speaker 1

So there's the school of thought that, you know, 8.1. As a causal marker for AMKD was only discovered about 11 years ago. And FDA, when the other sponsor went to the FDA for a registration study, FDA not knowing the disease very well went with proteinuria plus GFR slope. Yeah, it was before the parasol analysis. Exactly, so now we have had approvals in FSGS and IGAN using just proteinuria. Why doesn't that flow into AMKD where, in many ways, the disease progresses faster?

Jason Coloma, CEO

Yeah, I think the agency has always, I think, been consistent, just like they have in IGAN and FSGS, that they would take this in a data-driven approach and do this from an indication-by-indication basis. I think they've held true to that. And I think until this data and this type of analysis had been done, I think that was probably the easiest thing to do based off of limited data. I think going forward, I think that's something we would love to engage the agency on, is based off the analysis and our data, is there a possibility to look at proteinuria alone as the basis for accelerated approval? Now, more to come on that, but I think, you know, the data, especially for non-diabetic patients, seems to be clear in the correlation between proteinuria and EGFR outcome, not just slope. So I think that's important.

Speaker 1

Got it. Yeah. Given we have limited amount of time here, I want to switch to the Slick6A19 program. The PKU studies are enrolling. You should have some very good insights, call it middle of the year, back end of the year, next year. Could you just remind us how substantially different this is from the Janana program that eventually got acquired?

Jason Coloma, CEO

Yeah. So, I mean, in general, there's a couple of approaches in PKU treatment. One is having an enzyme substitution that basically allows for the phenylalanine in the blood to be properly handled. And then there are a couple of approved products, Cuvon and Suffiance, which are BH4 agonists, which are just cofactors that allow for the residual enzyme to be better at being able to break down the phenylalanine. SLC6A19 inhibition that was shown proof of concept by Janan, as you pointed out, doesn't rely on the residual enzyme to work. So it basically just gets rid of the plasma phi or the phenylalanine in the blood by just basically urinating it out. It's a nice, easy sort of biology to understand, and it's shown proof of concept in the ability to lower phenylalanine in the blood. So, as we were embarking on this program, you know, obviously the Janana data was in front of us and the molecule was, you know, sort of apparent. You know, we knew preclinically that we had more potency and we had better ADME than the compound. And so, that gave us at least a reason to believe that we might be able to show better pharmacodynamic effect that might be even proven in healthy volunteers by looking at a non-invasive biomarker urinary fee. And so what we did that in our phase one, we were able to demonstrate not only just the safety tolerability, but we were also able to show a pharmacodynamic effect by looking at that biomarker, because we knew in the literature. That they had a particular dose showed a tenfold increase over baseline of that particular marker. And then we had multiple doses, both QD and BID, that far exceeded that, like 40, 50 times, you know, in terms of relative to baseline. So that just reinforced what we saw pre-clinically, that we might have a better molecule, and then a reason to believe that we might be able to be more effective in lowering plasma fee in patients, PKU patients, in a proof-of-concept study. So that's what we're running now, the proof-of-concept study, the phase two. It's not open-label like our April 1 Horizon study. CIFR, as we call it, is placebo-controlled. There's a low dose, a high dose, and we're also exploring the possibility with combining with one of those BH4s to think about patients that may have some level of response to those BH4s, but can't get below a certain threshold to eventually become off of a medical diet, which is where most of the patients are actually using as their treatment option. And so if we can, you know, address this, both monotherapy in terms of the doses, that we can show more effective pharmacodynamic effect, lower the plasma fee, and also think about the number of patients that can get below a certain threshold. So as we kind of look at that, the literature has also kind of put a guide there in terms of the benchmark. So I think, you know, in clinic, in PKU patients, the other program that you mentioned, at least at one dose, showed a 40% reduction in plasma fee. And then if you look at the 19 patients that they treated in that phase 1-2, they had three of the 19 get below 360. And 360 is sort of the level of micromolars of plasma fee that physicians can start to think about transitioning their patients off the medical diet. Right, so if we know those are the benchmarks, we have reasons to believe based off our preclinical and now our phase one data, and obviously we'll have the data to try to reinforce our best in class profile in 27.

Speaker 1

Got it, and the renal signal that you saw on the heli volunteers, that comes up in discussions. Do you have a better sense of what we should expect in PKU patients? Oh, you mean CKD patients?

Jason Coloma, CEO

Oh, yeah. In CKD patients, we are running another proof of concept study to complement or even replace patients that are on important therapy, SGLT2 inhibitors. So we've described for the first time at least high level what that trial can look like, which we are looking at patients that could be on ACE ARBs and or SGLT2s, and in particular have diabetes sort of DKD patients in that study. And what we want to see, ideally, in that particular study is, you know, a certain percentage drop of proteinuria, or UACR, to show proof of concept, as well as potentially show what we saw in the healthy volunteers, which is called this EGFR dip, to represent that we have this hemodynamic effect, which all renal protective agents that are approved on the market, including ACE-ARBS, SGLT2, even GLP-1s, they all show this initial dip. which then have prolonged benefit. And if we can show those two things, I think we'll have shown proof of concept in this mechanism.

Speaker 1

Well, unfortunately, we just ran the clock and looking forward to a very productive 2027.

Jason Coloma, CEO

Yeah, thank you, Dejit.

Speaker 1

Appreciate the time. Thank you so much.

Jason Coloma, CEO

Yeah, thank you for having us.